RITA LUTZ: Open Payments
NPI 1982195285 · COLUMBIA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,127 in 219 payments from 23 companies in 2025. Trend: 2023 $3,318 · 2024 $4,730 · 2025 $4,127
Food & beverage: $4,050Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $864 |
| Janssen Biotech, Inc. | 18 | $440 |
| Aimmune Therapeutics, Inc. | 23 | $435 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $363 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $260 |
| Ardelyx, Inc. | 14 | $256 |
| Madrigal Pharmaceuticals | 9 | $229 |
| Gilead Sciences, Inc. | 25 | $206 |
| Celltrion USA Inc. | 9 | $193 |
| Lilly USA, LLC | 6 | $175 |
Products named: TREMFYA, ZENPEP, XIFAXAN, RINVOQ, IBSRELA, ENTYVIO, REZDIFFRA, LINZESS.
Industry payments across MO — which companies pay providers there.
